Details for Patent: 8,759,401

« Back to Dashboard

Which drugs does patent 8,759,401 protect, and when does it expire?

Patent 8,759,401 protects AKTEN and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 8,759,401

Title:	Aqueous gel formulation and method for inducing topical anesthesia
Abstract:	Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.
Inventor(s):	Abu Alam, Elias Reichel, Brandon Busbee
Assignee:	Thea Pharma Inc , Medtech Products Inc
Application Number:	US13/961,453
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 8,759,401

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Thea Pharma	AKTEN	lidocaine hydrochloride	GEL;OPHTHALMIC	022221-001	Oct 7, 2008		RX	Yes	Yes			Y			METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE

International Family Members for US Patent 8,759,401

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2043601
World Intellectual Property Organization (WIPO)	2008014036